Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct Clinical Trial

Official title:
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Status Completed

Clinical Trial Summary

The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02115542
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Completed
Phase	Phase 2
Start date	June 5, 2014
Completion date	September 20, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00386516` - Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer	Phase 2
Recruiting	`NCT05179824` - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting	`NCT05849480` - A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)	Phase 1/Phase 2
Recruiting	`NCT03821025` - Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction	N/A